SCHEMBL9966006

SCHEMBL9966006

C[C@H]1CN(C)CCN1Cc1nc2ccccc2o1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.45
MAPT P10636 2/20 0.45
RAB9A P51151 2/20 0.45
TP53 P04637 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
LMNA P02545 1/20 0.42
DRD3 P35462 6/20 0.42
DRD2 P14416 4/20 0.42
DRD4 P21917 4/20 0.42
LOXL2 Q9Y4K0 1/20 0.41
USP2 O75604 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
DRD1 P21728 2/20 0.39
PIK3CB P42338 1/20 0.39
OPRK1 P41145 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
HTT P42858 1/20 0.37
GFER P55789 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9963405 0.84 RAB9A (0.42) NPC1MAPTRAB9ATP53SMN1; SMN2
SCHEMBL9933061 0.79 NPC1 (0.44) NPC1MAPTRAB9ATP53SMN1; SMN2
SCHEMBL9934722 0.77 TBK1 (0.45) NPC1RAB9ASMN1; SMN2LMNAKMT2A
SCHEMBL9963107 0.77 TBK1 (0.45) NPC1RAB9ASMN1; SMN2LMNAKMT2A
SCHEMBL9934812 0.75 KMT2A (0.46) NPC1MAPTRAB9ATP53SMN1; SMN2
SCHEMBL14930169 0.71 MC4R (0.53) MAPT
SCHEMBL9965922 0.69 HRH3 (0.51) SMN1; SMN2LMNADRD4KMT2A
SCHEMBL5334548 0.68 DRD3 (0.59) NPC1MAPTRAB9ATP53SMN1; SMN2
SCHEMBL5633385 0.68 NPC1 (0.54) NPC1MAPTRAB9ATP53SMN1; SMN2
SCHEMBL1514939 0.67 SOS1 (0.67) NPC1MAPTRAB9ATP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 NPC1 1934/4885MAPT 2512/4885RAB9A 1162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.